Elevar Therapeutics Submits Marketing Authorization Application to European Medicines Agency for Lirafugratinib as a Treatment for Patients with Advanced/Metastatic Cholangiocarcinoma (CCA) Harboring FGFR2 Fusions or Rearrangements
Submission initiates regulatory process in European Union following U.S. submission, expanding global market presence Lirafugratinib is a highly selective, irreversible FGFR2 inhibitor differentiated from existing pan-FGFR therapies FORT LEE, N.J., Sept. 15 – Elevar Therapeutics, Inc., a majority-owned subsidiary of
